<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943900</url>
  </required_header>
  <id_info>
    <org_study_id>CA102-003</org_study_id>
    <nct_id>NCT04943900</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels&#xD;
      and preliminary antitumor activity of BMS-986416 when administered alone and in combination&#xD;
      with Nivolumab in participants with select advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">November 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to death</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol-defined maximum tolerated dose (MTD) or maximum administered dose (MAAD)</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986416</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of BMS-986416</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of BMS-986416</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) per Investigator assessment</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) using RECIST 1.1 per Investigator assessment</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QTcF</measure>
    <time_frame>Up to 100 days after the last treatment of study intervention(s)</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1A: Monotherapy (BMS-986416)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: Combination Therapy (BMS-986416 + Nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986416</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A: Monotherapy (BMS-986416)</arm_group_label>
    <arm_group_label>Part 1B: Combination Therapy (BMS-986416 + Nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1B: Combination Therapy (BMS-986416 + Nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit:&#xD;
&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with histologically or cytologically confirmed locally advanced&#xD;
             unresectable, metastatic, or recurrent select solid tumor&#xD;
&#xD;
          -  Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC),&#xD;
             Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC),&#xD;
             Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal&#xD;
             adenocarcinoma (PDAC)&#xD;
&#xD;
          -  Resistant/refractory to or intolerant of existing standard therapies known to provide&#xD;
             clinical benefit&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1&#xD;
             (RECIST v 1.1)&#xD;
&#xD;
          -  Disease amenable to serial biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome&#xD;
&#xD;
          -  Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose&#xD;
             aspirin, which is permitted)&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information, Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986416</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Opdivo</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>Urothelial carcinoma (UC)</keyword>
  <keyword>Squamous cell carcinoma of the head and neck (SCCHN)</keyword>
  <keyword>Hepatocellular carcinoma (HCC)</keyword>
  <keyword>Microsatellite-stable colorectal carcinoma (MSS CRC)</keyword>
  <keyword>Pancreatic ductal adenocarcinoma (PDAC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

